title: [Effects of subcutaneous administration of sandostatine (SMS 201.995) in 18 cases of thyroid medullary cancer].
abstract: Recent studies have suggested that somatostatin could reduce calcitonin plasma levels (CT) in normal subjects and in medullary thyroid carcinoma (MTC). The aim of this study was to examine the usefulness of the somatostatin analog, sandostatine (SMS 201.995) in MTC with elevated residual CT levels post-thyroidectomy with or without metastases. 18 patients (17-64 years, 12 men and 8 women) with CT greater than 850 pg/ml (N less than 150 pg/ml) and with metastases in 12 cases, were studied. MTC was sporadic in 11 cases, familial in 4 cases and of undefined form in 3. Initial posology was 300 micrograms/d of sandostatin (3 injections/day). It was then increased by 300 micrograms/d every 9 day till a maximum of 1500 micrograms/d. Treatment duration was 37 days in 11 cases and 60 days in 7 cases. Plasma CT and carcinoembryonic antigen levels (CEA) were measured before treatment and at the end of each dosage plateau. Morphologic evaluation of metastases was done at 0, 30, 60 days. 7/18 patients were reevaluated 2 to 8 months after with drawal of sandostatine. Treatment was well tolerated. Flushes improved in 4 out of 5 cases but diarrhea in only 2 out of 9 patients. Sandostatine was without any effect on plasma CEA. Heterogenous responses were observed for plasma CT levels (CT decreases greater than 20% in 8/18 patients when 900 to 1500 micrograms/day were administered). Patients were subdivised into 3 groups according to CEA levels and presence or absence of metastases. Group A (n = 9) had elevated CEA levels (greater than 10 mg/ml) and metastases.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Endocrinologie, Hôpital Avicenne, Bobigny.
authors.forename: E
authors.initials: E
authors.lastname: Modigliani
authors.forename: J M
authors.initials: JM
authors.lastname: Guliana
authors.forename: M
authors.initials: M
authors.lastname: Maroni
authors.forename: J P
authors.initials: JP
authors.lastname: Guillausseau
authors.forename: G
authors.initials: G
authors.lastname: Chabrier
authors.forename: J L
authors.initials: JL
authors.lastname: Dupont
authors.forename: J
authors.initials: J
authors.lastname: Caron
authors.forename: P
authors.initials: P
authors.lastname: Roger
authors.forename: M
authors.initials: M
authors.lastname: Bentata Pessayre
authors.forename: C
authors.initials: C
authors.lastname: Jacob
mesh_terms: D000293:Adolescent; D000328:Adult; D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D002272:Carcinoembryonic Antigen; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide; D015282:Octreotide
vernacular_title: Effets de l'administration sous cutanée de la sandostatine (SMS 201.995) en sous cutané dans 18 cas de cancer médullaire du corps thyroïde.